Loading people...
Hiroyuki Nagasawa is an Investor at Taiho Ventures based in Menlo Park, California. In this role, he allocates capital from a $400 million corporate venture fund to back early-stage biotechnology startups, with a specific emphasis on oncology and platform technologies. Prior to his current position, he served as an Investment Manager and Venture Partner at Remiges Ventures, where he evaluated life sciences investments. Nagasawa also previously worked as a Manager at Taiho Pharmaceutical, the corporate parent organization of his current venture capital firm. His investment scope involves supporting a broader corporate portfolio of over 25 life sciences companies, which includes notable clinical-stage developers like Arcus Biosciences and Orna Therapeutics. Nagasawa currently focuses on identifying seed and Series A stage therapeutic companies advancing novel biologics and small molecule drug discovery across the global market.
Hiroyuki Nagasawa is a key Investor at Taiho Ventures, the dedicated corporate venture capital fund of Taiho Pharmaceutical Co., Ltd. In this capacity, Mr. Nagasawa plays a crucial role in scouting, evaluating, and executing strategic investments in innovative startups that align with Taiho Pharmaceutical's core therapeutic areas and long-term strategic goals. His work is vital in expanding Taiho's reach into emerging technologies and novel therapeutic modalities.
Taiho Ventures, where Hiroyuki Nagasawa contributes significantly, primarily focuses on early-stage companies across various healthcare sectors. The investment focus areas typically include oncology, a cornerstone of Taiho Pharmaceutical's research and development, as well as rare diseases, neuroscience, and digital health solutions that can enhance patient care or drug discovery processes. Investors like Mr. Nagasawa seek out disruptive technologies and platforms, novel drug candidates, and innovative medical devices that have the potential to address unmet medical needs and create significant value for patients and the broader healthcare ecosystem. This strategic approach ensures that Taiho Pharmaceutical remains at the forefront of medical innovation.
While specific details of Hiroyuki Nagasawa's individual career background are not publicly detailed, his role as an Investor at a prominent corporate venture fund suggests a strong foundation in life sciences, venture capital, or corporate development within the pharmaceutical industry. Professionals in this position typically possess a deep understanding of scientific principles, clinical development pathways, market dynamics, and financial analysis. This multidisciplinary expertise is essential for identifying high-potential investments and guiding portfolio companies towards successful outcomes. His contributions help Taiho Ventures build a robust portfolio of companies poised to make a meaningful impact on global health.
Taiho Ventures has a track record of investing in companies that are developing cutting-edge therapies and technologies. While specific notable investments directly attributable to Mr. Nagasawa are not widely publicized, his involvement as an Investor means he is integral to the process of identifying and supporting the innovative companies that form Taiho Ventures' diverse portfolio. These investments are designed not only to generate financial returns but also to foster strategic collaborations and provide Taiho Pharmaceutical with access to groundbreaking science and technology, ultimately benefiting patients worldwide. Hiroyuki Nagasawa's dedication to identifying and nurturing these promising ventures underscores Taiho Ventures' commitment to driving the future of healthcare.
Hiroyuki Nagasawa is an Investor at Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical. He focuses on identifying and investing in innovative healthcare and biotech startups.
Hiroyuki Nagasawa, through Taiho Ventures, invests in early-stage companies developing solutions in oncology, rare diseases, neuroscience, and digital health, aligning with Taiho Pharmaceutical's strategic interests.
Hiroyuki Nagasawa works at Taiho Ventures, which is the corporate venture capital fund of Taiho Pharmaceutical Co., Ltd.
